Health Condition 1: L811- Chloasma
Conditions
Interventions
Intervention1: Inj Tranexamic acid: 4 mg/ml of TXA,intradermal injections of TXA was administered over the hyper-pigmented patches, separating each prick with a 1 cm distance injecting one unit from i
Sponsors
Ashrita Krishna
Eligibility
Inclusion criteria
Inclusion criteria: 1)Either gender 2) Age range of 20 to 50 years 3)Patients suffering from melasma. 4)Patients who didn t respond to conventional topical therapy for melasma
Exclusion criteria
Exclusion criteria: 1)Pregnancy and lactation 2)patients with known platelet dysfunction 3)Those with prior history of allergy to tranexamic acid (may june) 4)Intake of any photosensitizing drugs 5) Known allergy to TXA. 6) Women on oral contraceptive pills and hormone replacement therapy. 7) Patients on any topical therapy for melasma in the past 3 months. 8) Critical thrombocytopenia less than 50,000/mcl. 9)Any history of hemodynamic instability.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of intralesional Tranexamic acid versus intralesional Inj platelet rich plasma in the treatment of melasma. Timepoint: 20 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| nilTimepoint: nil | — |
Countries
India
Contacts
Public ContactAshrita Krishna
Hassan Institute Of Medical Sciences
Outcome results
None listed